arrow
N

Nikolaj Frost

charite-universitaetsmedizin berlin
H指数:22
被引数:1,816

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Hospital Costs and Pleural Complications of Electromagnetic Navigational Bronchoscopy Versus CT-Guided Transthoracic Needle Biopsy: A German Multicentre Matched Analysis

电磁导航支气管镜与CT引导经胸壁针吸活检的住院费用及胸膜并发症:一项德国多中心配对分析

2026-11-130
OA
A single-cell lung cancer atlas reveals cellular and molecular drivers of metastasis and clinical outcome

单细胞肺癌图谱揭示转移和临床结局的细胞和分子驱动因素

2026-11-120
OAAI
Clinical management and outcomes of relapsed NSCLC after chemoradiotherapy and durvalumab consolidation: real-world evidence from Germany

德国真实世界证据:化疗联合放疗后复发NSCLC的临床管理与结局:度伐利尤单抗巩固治疗后的情况

2026-07-230
PRE
Liquid biopsy-based detection of acquired MET resistance enables sequential targeted therapy in MET fusion-positive NSCLC

基于液体活检检测获得性MET耐药性使MET融合阳性NSCLC患者能够进行序贯靶向治疗

2026-04-210
OA
Clinical outcomes with perioperative nivolumab by nodal status in patients with stage III resectable NSCLC: phase 3 CheckMate 77T exploratory analysis

III期可切除NSCLC患者围手术期nivolumab的临床结局: CheckMate 77t 3期探索性分析

2026-01-080
OAAI
PET/CT-Guided Management of Immune Checkpoint Blockade and Post-Treatment Multi-Modal Profiling in Long-Term Responders with Metastatic Lung Cancer in the National Network Genomic Medicine Lung Cancer Germany (nNGM)

PET/CT引导下对转移性肺癌长期应答者的免疫检查点阻断管理及治疗后多模式分析——德国国家网络基因组医学肺癌项目(nNGM)

2025-12-300
OAAI
Independent Validation of a Machine Learning Classifier for Predicting Mediastinal Lymph Node Metastases in Non-Small Cell Lung Cancer Using Routinely Obtainable [18F]FDG-PET/CT Parameters

使用常规可获得的[18F]FDG-PET/CT参数对预测非小细胞肺癌纵隔淋巴结转移的机器学习分类器进行独立验证

2025-12-010
OAAI
AI-powered spatial cell phenomics enhances risk stratification in non-small cell lung cancer

人工智能驱动的空间细胞表型学增强非小细胞肺癌的风险分层

2025-11-030
OAAI
HIGH-GRADE IMMUNE-RELATED ADVERSE EVENTS AND PATIENT OUTCOMES FOLLOWING POST-OPERATIVE CHECKPOINT INHIBITION IN RESECTED BRAIN METASTASES: A RETROSPECTIVE COHORT STUDY

高级别免疫相关不良事件及术后检查点抑制剂治疗切除脑转移瘤患者的预后:一项回顾性队列研究

2025-10-010
PRE
First-line nivolumab plus ipilimumab in pleural mesothelioma: Efficacy and safety data from the real-world MesoNet study

一线纳武利尤单抗联合伊匹木单抗治疗恶性胸膜间皮瘤:来自真实世界MesoNet研究的疗效与安全性数据

2025-08-050
OAAI
Treatment Sequences in BRAF-V600–Mutated NSCLC: First-Line Targeted Therapy Versus First-Line (Chemo-) Immunotherapy

BRAF-V600-Mutated NSCLC的治疗顺序: 一线靶向治疗与一线 (化疗) 免疫治疗

2025-05-080
OAAI
Clinical characteristics and outcomes in leptomeningeal disease with or without brain metastasis: insights from an explorative data analysis of the Charité LMD registry

有或没有脑转移的软脑膜疾病的临床特征和结局: 来自charit é LMD注册中心的探索性数据分析的见解

2025-02-110
OAAI
TTF-1 negativity in synchronous M1b/M1c wildtype lung adenocarcinoma brain metastases predicts worse survival with increased risk of intracranial progression
2024-12-040
OAAI
SYSTEMIC AND LOCAL THERAPIES BEFORE AND AFTER DIAGNOSIS OF LEPTOMENINGEAL DISEASE IN PATIENTS WITH BRAIN METASTASES: AN EXPLORATIVE, SINGLE-CENTER RETROSPECTIVE COHORT STUDY
2024-10-170
PRE
TTF-1 is a highly sensitive but not fully specific marker for pulmonary and thyroidal cancer: a tissue microarray study evaluating more than 17,000 tumors from 152 different tumor entities

TTF-1是肺癌和甲状腺癌的高度敏感但不完全特异性的标志物: 一项组织微阵列研究评估了来自152个不同肿瘤实体的17,000多种肿瘤

2024-10-080
OAAI